FAQs

Insurance companies often take their cue regarding what they will need to cover to stay viable in the market from "FDA approved" treatments and protocols. This is a prohibitive misuse of this label and how proper healthcare works. Though off-label use of FDA approved treatments (such as liquid antigen sublingual immunotherapy) is [...]

As with any compounded, complex treatment, there is an extremely large variation in the quality of available treatments and treatment programs. Allergies are extremely prevalent, and patients, physicians, and companies are all searching for ways to treat these allergies. Given the overall safety of sublingual immunotherapy, several companies have started to provide [...]

Quite simply, liquid multi-allergen sublingual immunotherapy training is not part of the typical allergy fellowship training program curriculum in the US. As such, without instruction on and exposure to this treatment during an allergist’s formal training years, few allergists have experience formulating and managing this treatment, nor have they seen first-hand the [...]

Yes. Sublingual immunotherapy (SLIT) drops can be adjusted to the right dose for each individual patient, making this an extremely safe form of controlled allergen exposure and immunotherapy. This is especially true when the treatment is designed and managed by a physician with appropriate proficiency in properly interpreting allergen testing (such as [...]

The "short answer" is that your initial course of SLIT at Allergenuity Health will typically be designed for 4-5 years, including a build-up phase of 1-3 years and an initial maintenance phase of 1-2 years. That being said, there is significant variation from this due to many factors, and it is very [...]

Improvement in chronic allergen-related symptoms is typically seen well within the first year - as quickly as within the first few months for some individuals, but may take several months or closer to a year in others - so it is important to not be discouraged if quick changes are not seen [...]